Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose

@inproceedings{Hanley2010EffectOR,
  title={Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose},
  author={Anthony J. G. Hanley and Bernard Zinman and Patrick J. Sheridan and Salim Yusuf and Hertzel C. Gerstein},
  booktitle={Diabetes care},
  year={2010}
}
OBJECTIVE The objective of this study was to determine the degree to which ramipril and/or rosiglitazone changed beta-cell function over time among individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) who participated in the Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) Trial, which evaluated whether ramipril and/or rosiglitazone could prevent or delay type 2 diabetes in high-risk individuals. RESEARCH DESIGN AND METHODS The… CONTINUE READING
14 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone

  • Investigators Trial, HC Gerstein, +11 authors RR. Holman
  • Lancet
  • 2006

 - Cell glucose toxicity , lipo - toxicity , and chronic oxidative stress in type 2

  • SM Haffner, AS Greenberg, WM Weston, H Chen, K Williams, MI Freed
  • DIABETES
  • 2004

Similar Papers

Loading similar papers…